V
Viridos
A leader in the field of synthetic biology, advancing genomics to better life
About Viridos
Viridos is a biotechnology startup that is focused on developing advanced biofuel technology to mitigate climate change. The company's primary product is algal biofuel, a renewable energy source that offers a solution for industries struggling to decarbonize. Viridos operates in the renewable energy market, specifically in the biofuel sector, serving clients across various industries that are seeking sustainable energy alternatives.
Read full description
The company's business model revolves around the development and commercialization of its proprietary algal biofuel technology. It generates revenue by selling this biofuel to industries that are transitioning away from fossil fuels. Viridos has also formed a strategic partnership with ExxonMobil, a major player in the energy sector, to bring algae biofuel to the global stage. This partnership is aimed at decarbonizing heavy transportation, a sector that has traditionally been reliant on fossil fuels.
In addition to its biofuel technology, Viridos has developed a proprietary RNA replicon platform for creating innovative vaccines and therapeutics. This platform uses advanced genomics and bioengineering to selectively stimulate the immune system and deliver targeted therapies produced within the body.
The company's mission is to replace unsustainable systems with products and processes that reduce greenhouse gas emissions, ultimately contributing to a future where everyone can thrive. Every position at Viridos supports this higher purpose of mitigating climate change.
At a glance
- Status
- Operational
- Founded
- 2005
- Headquarters
- San Diego, United States
- Employees
- 47
- Open positions
- None listed
- Dealroom signal
- 64.5/100
- Sector
- Aviation, Intellectual Property, Biotechnology, DNA, Algae, Genetics and genomics, Synthetic Biology, Crispr, Biofuel, Genome Engineering, Alternative Protein, Sustainable Development Goals, Aviation and Aerospace, Pay Per Result
- Business model
- Manufacturing
- Investment activity
- 1 company, latest Jan 2013
- Capital deployed
- $0
- Preferred round
- CORPORATE SPINOUT
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Mar 2023 | $25M | $250M | Breakthrough Energy Ventures · United Airlines Venture · Chevron | ↗ |
| GRANTOther financing | Apr 2022 | $0 | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Viridos is 1.6K monthly website visits, up 344.4% over the last three months. Viridos's team declined 6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Frontier Venture Capital- BIBiotechonomy
BP Ventures
LifeTechnologies
OS Fund- LBLung Biotechnology
Breakthrough Energy Ventures
United Airlines Venture
Chevron
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Viridos on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Viridos’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.